牛牛AI助理已提取核心訊息
On March 1, 2024, Adial Pharmaceuticals, Inc. entered into a material definitive agreement with a holder of the company's existing warrants, resulting in the exercise of warrants for approximately 1,150,000 shares of common stock at $2.82 per share. This transaction, which closed on March 6, 2024, generated gross proceeds of about $3.5 million for Adial Pharmaceuticals, before accounting for placement agent fees and other expenses. In addition to the exercise of existing warrants, the company issued new unregistered Series C Warrants for the purchase of 2,300,000 shares of common stock. The company has agreed to file a registration statement for the resale of the new warrant shares within 45 days of the transaction's initial closing. The net proceeds from this transaction are intended for working capital and...Show More
On March 1, 2024, Adial Pharmaceuticals, Inc. entered into a material definitive agreement with a holder of the company's existing warrants, resulting in the exercise of warrants for approximately 1,150,000 shares of common stock at $2.82 per share. This transaction, which closed on March 6, 2024, generated gross proceeds of about $3.5 million for Adial Pharmaceuticals, before accounting for placement agent fees and other expenses. In addition to the exercise of existing warrants, the company issued new unregistered Series C Warrants for the purchase of 2,300,000 shares of common stock. The company has agreed to file a registration statement for the resale of the new warrant shares within 45 days of the transaction's initial closing. The net proceeds from this transaction are intended for working capital and other general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the transaction, receiving a cash fee, management fee, expense allowance, and legal fees, along with warrants to purchase 69,000 shares of common stock. The new warrants are exercisable immediately and will be valid for eighteen months from the date of issuance. The company has also committed to not issuing any additional common stock or equivalents for 30 days following the closing of the transaction.
2024年3月1日，Adial Pharmicals, Inc.與公司現有認股權證的持有人簽訂了重要的最終協議，最終以每股2.82美元的價格行使了約115萬股普通股的認股權證。該交易於2024年3月6日完成，在不計入配售代理費和其他費用之前，爲阿迪爾製藥公司創造了約350萬美元的總收益。除了行使現有認股權證外，該公司還發行了新的未註冊C系列認股權證，用於購買2,300,000股普通股。該公司已同意在交易首次完成後的45天內提交轉售新認股權證股份的註冊聲明。本次交易的淨收益用於營運資金和其他一般公司用途。H.C. Wainwright & Co. 擔任該交易的獨家配售代理，獲得現金費、管理費、支出補貼和律師費，以及購買69,000股普通股的認股權證。新的認股權證可立即行使，自發行之日起有效期爲十八個月。該公司還承諾在交易完成後的30天內不發行任何額外的普通股或等價物。
2024年3月1日，Adial Pharmicals, Inc.與公司現有認股權證的持有人簽訂了重要的最終協議，最終以每股2.82美元的價格行使了約115萬股普通股的認股權證。該交易於2024年3月6日完成，在不計入配售代理費和其他費用之前，爲阿迪爾製藥公司創造了約350萬美元的總收益。除了行使現有認股權證外，該公司還發行了新的未註冊C系列認股權證，用於購買2,300,000股普通股。該公司已同意在交易首次完成後的45天內提交轉售新認股權證股份的註冊聲明。本次交易的淨收益用於營運資金和其他一般公司用途。H.C. Wainwright & Co. 擔任該交易的獨家配售代理，獲得現金費、管理費、支出補貼和律師費，以及購買69,000股普通股的認股權證。新的認股權證可立即行使，自發行之日起有效期爲十八個月。該公司還承諾在交易完成後的30天內不發行任何額外的普通股或等價物。
有用
沒用